openPR Logo
Press release

Non-Alcoholic Fatty Liver Disease (NAFLD) Market to Rise at 5.98% CAGR, Reaching USD 3.8 Billion by 2035

07-18-2025 12:58 PM CET | Health & Medicine

Press release from: Market Research Future

/ PR Agency: MRFR
Non-Alcoholic Fatty Liver Disease (NAFLD) Market to Rise

BREAKING: The Non-Alcoholic Fatty Liver Disease NAFLD market is positioned to become the #1 game-changing force in the global Healthcare sector by 2035, creating unprecedented growth opportunities for manufacturers, technology providers, enterprise clients, solution developers and strategic investors worldwide.

This exclusive deep-dive report delivers comprehensive analysis of the rapidly evolving Non-Alcoholic Fatty Liver Disease NAFLD industry, uncovering breakthrough technological advancements, critical market milestones and transformative future projections. It explores the revolutionary impact of Non-Alcoholic Fatty Liver Disease NAFLD across multiple Healthcare applications, while dissecting key market dynamics including accelerating growth catalysts, potential barriers, untapped opportunities and strategic challenges.

Furthermore, this report presents authoritative market forecasting with current valuation assessments and detailed projections extending through 2035. These data-driven insights are grounded in real-world adoption analytics and extensive primary research validation. The analysis segments both existing and projected market opportunities within the Non-Alcoholic Fatty Liver Disease NAFLD ecosystem from 2025 to 2035.

Non-Alcoholic Fatty Liver Disease NAFLD Market Intelligence: Revenue Projections & Geographic Analysis (Global & Regional Breakdown):

As per MRFR analysis, the Non-Alcoholic Fatty Liver Disease NAFLD Market Size was estimated at 1.89 (USD Billion) in 2023. The Non-Alcoholic Fatty Liver Disease NAFLD Market Industry is expected to grow from 2.01(USD Billion) in 2024 to 3.8 (USD Billion) by 2035. The Non-Alcoholic Fatty Liver Disease NAFLD Market CAGR (growth rate) is expected to be around 5.98% during the forecast period (2025 - 2035).

The NAFLD market focuses on the diagnosis, monitoring, and treatment of a chronic liver condition caused by fat buildup in the liver not linked to alcohol use. NAFLD is increasingly prevalent due to rising obesity, diabetes, and metabolic syndrome worldwide. The market includes diagnostics (imaging, liver function tests), therapeutics (including emerging NASH drugs), lifestyle management programs, and digital health platforms. As the disease progresses silently, early intervention and accurate monitoring are critical.

🚀 Download Your Exclusive Free Sample of the Non-Alcoholic Fatty Liver Disease NAFLD Market Intelligence Report- https://www.marketresearchfuture.com/sample_request/42175

The Digital Transformation Revolution: How AI is Disrupting the Non-Alcoholic Fatty Liver Disease NAFLD Healthcare Landscape

AI is emerging as a vital tool in identifying and managing NAFLD and its advanced stage-non-alcoholic steatohepatitis (NASH). AI algorithms can process liver imaging data, electronic health records (EHRs), and lab results to detect early disease signs, stratify risk, and personalize interventions. AI-assisted diagnostic tools also enable non-invasive assessment of liver fibrosis, reducing the need for biopsies.

Next-Generation AI Innovations Accelerating Non-Alcoholic Fatty Liver Disease NAFLD Market Expansion

Innovations include AI-powered liver ultrasound and elastography analysis tools, machine learning models for predicting NAFLD progression, and digital platforms that integrate wearable data to monitor weight, glucose, and liver health. AI is also aiding in clinical trial design for NASH therapeutics by identifying eligible patient populations based on large-scale real-world data.

Secure Your Complete Non-Alcoholic Fatty Liver Disease NAFLD Market Analysis Report Today- https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=42175

Non-Alcoholic Fatty Liver Disease NAFLD Industry Performance Metrics (2023-2025)

The NAFLD market is projected to grow at a CAGR of 10.5% from 2023 to 2025, reaching USD 6.3 billion by 2025. North America dominates due to high obesity rates and strong diagnostic infrastructure. Europe and Asia-Pacific are also witnessing increased diagnosis and research funding. AI integration into NAFLD diagnostics and care management grew significantly in top liver disease centers during this period.

Game-Changing Trends Defining the Future of AI-Powered Non-Alcoholic Fatty Liver Disease NAFLD Solutions

Key trends include the development of non-invasive diagnostics, a surge in NASH drug pipeline activity, growing use of digital lifestyle management apps, and expansion of AI-supported population health monitoring systems. Pharma companies are increasingly collaborating with tech firms to integrate AI into drug development and liver care platforms.

Market Leaders in Non-Alcoholic Fatty Liver Disease NAFLD Innovation - Discover the Companies Revolutionizing Healthcare here- https://www.marketresearchfuture.com/reports/non-alcoholic-fatty-liver-disease-market-42175

Strategic Challenges and Risk Factors in AI-Driven Non-Alcoholic Fatty Liver Disease NAFLD Implementation

Challenges include underdiagnosis due to asymptomatic presentation, lack of FDA-approved drugs for NASH, high disease heterogeneity, and the complexity of data integration in AI systems. Data privacy and validation of AI models in diverse populations remain critical for real-world adoption.

The Future Vision: Non-Alcoholic Fatty Liver Disease NAFLD Market Transformation by 2035

Future AI applications will focus on continuous liver health monitoring via wearables, real-time dietary tracking, and digital twins to simulate treatment responses. AI will support earlier diagnosis, individualized therapy, and more efficient drug development pipelines, especially for NASH.

Access the Official Industry Press Release - Get Latest Market Updates- https://www.marketresearchfuture.com/reports/non-alcoholic-fatty-liver-disease-market-42175

Final Thoughts: Capitalizing on the AI-Driven Non-Alcoholic Fatty Liver Disease NAFLD Revolution in Global Healthcare

📊 What's Inside This Report:

Comprehensive market sizing and forecasting
Competitive landscape analysis
Technology trend assessment
Regional market breakdowns
Investment opportunity mapping
Risk and challenge evaluation

Access more Healthcare Full Report - Limited Time Offer

Antihypertensive Drugs Market - https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347

Fetal Bovine Serum Market - https://www.marketresearchfuture.com/reports/fetal-bovine-serum-market-7377

Doxorubicin Market - https://www.marketresearchfuture.com/reports/doxorubicin-market-7376

Albumin Market - https://www.marketresearchfuture.com/reports/albumin-market-7442

Poultry Vaccines Market - https://www.marketresearchfuture.com/reports/poultry-vaccines-market-7515

Generic Injectables Market - https://www.marketresearchfuture.com/reports/generic-injectables-market-7512

Transdermal Drug Delivery Systems Market - https://www.marketresearchfuture.com/reports/transdermal-drug-delivery-systems-market-7545

US Neuroprosthetics Market - https://www.marketresearchfuture.com/reports/us-neuroprosthetics-market-15551

US Fibromyalgia Treatments Market - https://www.marketresearchfuture.com/reports/us-fibromyalgia-treatments-market-15950

US Bronchitis Market - https://www.marketresearchfuture.com/reports/us-bronchitis-market-16652

"About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

we are launching ""Wantstats"" the premier statistics portal for market data in comprehensive charts and stats format, providing forecasts, regional and segment analysis. Stay informed and make data-driven decisions with Wantstats.
"

"Contact:

Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com"

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Alcoholic Fatty Liver Disease (NAFLD) Market to Rise at 5.98% CAGR, Reaching USD 3.8 Billion by 2035 here

News-ID: 4109948 • Views: …

More Releases from Market Research Future

Global Small Boat Industry Sees Growing Demand Amid Rising Recreational Boating and Coastal Activities
Global Small Boat Industry Sees Growing Demand Amid Rising Recreational Boating …
As per the latest analysis by Market Research Future, the Small Boats Market Size was estimated at 17.12 (USD Billion) in 2024. The Small Boats Market Industry is expected to grow from 17.88 (USD Billion) in 2025 to 26.41 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.43% during the forecast period (2025 - 2034). The global small boat industry is witnessing significant growth, driven…
Automotive Trim Market Attaining USD 193.22 Billion till 2034 | Innovations Redefine Vehicle Aesthetics and Functionality
Automotive Trim Market Attaining USD 193.22 Billion till 2034 | Innovations Rede …
As per the latest analysis by Market Research Future, the Automotive Trim Market Size was estimated at 140.30 (USD Billion) in 2024. The Automotive Trim Market Industry is expected to grow from 144.87 (USD Billion) in 2025 to 193.22 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 3.25% during the forecast period (2025 - 2034). The automotive industry is witnessing a significant transformation in vehicle…
Leading Automotive Technology Firms Expand Fuel Level Sensor Solutions for Next-Generation Vehicles | Robert Bosch Gmbh, Technoton
Leading Automotive Technology Firms Expand Fuel Level Sensor Solutions for Next- …
As per the latest analysis by Market Research Future, Automotive Fuel Level Sensor Market Size was valued at USD 5,788.04 million in 2024. The Automotive Fuel Level Sensor market industry is projected to grow from USD 6,008.32 million in 2025 to USD 9,201.90 million by 2035, exhibiting a compound annual growth rate (CAGR) of 4.35% during the forecast period (2024 - 2035). With the global automotive industry focused on precision,…
Valet Parking Technology Gains Momentum as Urban Mobility and Smart Infrastructure Evolve | Market Growth with 15.62% CAGR
Valet Parking Technology Gains Momentum as Urban Mobility and Smart Infrastructu …
As per the latest analysis by Market Research Future, the Valet Parking Technology Market Size was estimated at 1.41 (USD Billion) in 2024. The Valet Parking Technology Market Industry is expected to grow from 1.63 (USD Billion) in 2025 to 6.01 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 15.62% during the forecast period (2025 - 2034). Valet parking technology is emerging as a transformative…

All 5 Releases


More Releases for NAFLD

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA A …
Non Alcoholic Fatty Liver Disease (NAFLD) companies are BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Eli Lilly, AstraZeneca, Oasis Pharmaceuticals, LLC, Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Terns, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others. (Albany, United States) Non Alcoholic Fatty Liver Disease (NAFLD) pipeline constitutes 80+ key companies…
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA App …
Non Alcoholic Fatty Liver Disease (NAFLD) companies are Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Terns, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others. (Albany, United States) As per DelveInsight's assessment, globally, Non Alcoholic Fatty Liver…
Non Alcoholic Fatty Liver Disease (NAFLD) Market to Witness Growth by 2032, Esti …
DelveInsight's "Non Alcoholic Fatty Liver Disease (NAFLD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Non Alcoholic Fatty Liver Disease (NAFLD), historical and forecasted epidemiology as well as the Non Alcoholic Fatty Liver Disease (NAFLD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Non Alcoholic Fatty Liver Disease (NAFLD) market report provides current treatment practices, emerging drugs,…
Panthera leads the way in the UK with specialist research sites for NASH and NAF …
With access to leading hepatologists, biopsy theatres, fibroscans at specialist sites and ongoing mass screening programmes Panthera can help pharma and CROs find a treatment for this increasingly common, progressive, and life-threatening diseases. Non-Alcoholic steatohepatitis NASH and Non-Alcoholic Fatty liver Disease NAFLD have no approved medical treatments to treat these inflammatory conditions. Panthera is already involved with two trials with several more in the pipeline. There are over a thousand studies* underway…
New Drugs for Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato …
Researchmoz added Most up-to-date research on "Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018" to its huge collection of research reports. This report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players active in this space, and also features data for dormant and discontinued…
Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Report 2017-o …
Global Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Report 2017 presents a professional and deep analysis on the present state of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market 2017. In the first part, Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market study deals with the comprehensive overview of the Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales market, which consists of definitions,…